vs
Side-by-side financial comparison of FARMERS NATIONAL BANC CORP (FMNB) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
FARMERS NATIONAL BANC CORP is the larger business by last-quarter revenue ($71.5M vs $70.6M, roughly 1.0× Viridian Therapeutics, Inc.\DE). FARMERS NATIONAL BANC CORP runs the higher net margin — 20.5% vs -49.0%, a 69.5% gap on every dollar of revenue. On growth, Viridian Therapeutics, Inc.\DE posted the faster year-over-year revenue change (81958.1% vs 3.2%). FARMERS NATIONAL BANC CORP produced more free cash flow last quarter ($52.2M vs $-84.7M).
Farmers National Banc Corp (OH) is a regional financial holding company based in Ohio, the United States. It offers full-spectrum retail and commercial banking products, wealth management solutions, and insurance services, primarily catering to individual consumers, small and medium-sized enterprises, and local community clients in Ohio and adjacent Midwestern U.S. regions.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
FMNB vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $71.5M | $70.6M |
| Net Profit | $14.6M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | 24.8% | -56.7% |
| Net Margin | 20.5% | -49.0% |
| Revenue YoY | 3.2% | 81958.1% |
| Net Profit YoY | 1.7% | 54.9% |
| EPS (diluted) | $0.39 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $71.5M | — | ||
| Q3 25 | $70.8M | $70.6M | ||
| Q2 25 | $69.8M | — | ||
| Q1 25 | $67.8M | — | ||
| Q4 24 | $69.3M | — | ||
| Q3 24 | $70.3M | — | ||
| Q2 24 | $66.5M | — | ||
| Q1 24 | $63.4M | — |
| Q4 25 | $14.6M | — | ||
| Q3 25 | $12.5M | $-34.6M | ||
| Q2 25 | $13.9M | — | ||
| Q1 25 | $13.6M | — | ||
| Q4 24 | $14.4M | — | ||
| Q3 24 | $8.5M | — | ||
| Q2 24 | $11.8M | — | ||
| Q1 24 | $11.2M | — |
| Q4 25 | 24.8% | — | ||
| Q3 25 | 20.7% | -56.7% | ||
| Q2 25 | 23.4% | — | ||
| Q1 25 | 24.1% | — | ||
| Q4 24 | 25.5% | — | ||
| Q3 24 | 14.4% | — | ||
| Q2 24 | 21.3% | — | ||
| Q1 24 | 21.2% | — |
| Q4 25 | 20.5% | — | ||
| Q3 25 | 17.6% | -49.0% | ||
| Q2 25 | 19.9% | — | ||
| Q1 25 | 20.0% | — | ||
| Q4 24 | 20.8% | — | ||
| Q3 24 | 12.1% | — | ||
| Q2 24 | 17.7% | — | ||
| Q1 24 | 17.7% | — |
| Q4 25 | $0.39 | — | ||
| Q3 25 | $0.33 | — | ||
| Q2 25 | $0.37 | — | ||
| Q1 25 | $0.36 | — | ||
| Q4 24 | $0.38 | — | ||
| Q3 24 | $0.23 | — | ||
| Q2 24 | $0.31 | — | ||
| Q1 24 | $0.30 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $490.9M |
| Total DebtLower is stronger | $86.7M | — |
| Stockholders' EquityBook value | $485.7M | $503.0M |
| Total Assets | $5.2B | $577.1M |
| Debt / EquityLower = less leverage | 0.18× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | — | ||
| Q3 25 | — | $490.9M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $86.7M | — | ||
| Q3 25 | $86.6M | — | ||
| Q2 25 | $86.4M | — | ||
| Q1 25 | $86.3M | — | ||
| Q4 24 | $86.2M | — | ||
| Q3 24 | $86.0M | — | ||
| Q2 24 | $88.9M | — | ||
| Q1 24 | $88.8M | — |
| Q4 25 | $485.7M | — | ||
| Q3 25 | $465.9M | $503.0M | ||
| Q2 25 | $437.7M | — | ||
| Q1 25 | $429.1M | — | ||
| Q4 24 | $406.0M | — | ||
| Q3 24 | $439.7M | — | ||
| Q2 24 | $396.7M | — | ||
| Q1 24 | $397.0M | — |
| Q4 25 | $5.2B | — | ||
| Q3 25 | $5.2B | $577.1M | ||
| Q2 25 | $5.2B | — | ||
| Q1 25 | $5.2B | — | ||
| Q4 24 | $5.1B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $5.2B | — | ||
| Q1 24 | $5.1B | — |
| Q4 25 | 0.18× | — | ||
| Q3 25 | 0.19× | — | ||
| Q2 25 | 0.20× | — | ||
| Q1 25 | 0.20× | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | 0.20× | — | ||
| Q2 24 | 0.22× | — | ||
| Q1 24 | 0.22× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $60.0M | $-84.6M |
| Free Cash FlowOCF − Capex | $52.2M | $-84.7M |
| FCF MarginFCF / Revenue | 73.0% | -120.1% |
| Capex IntensityCapex / Revenue | 11.0% | 0.2% |
| Cash ConversionOCF / Net Profit | 4.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $85.8M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $60.0M | — | ||
| Q3 25 | $10.7M | $-84.6M | ||
| Q2 25 | $14.0M | — | ||
| Q1 25 | $15.7M | — | ||
| Q4 24 | $66.6M | — | ||
| Q3 24 | $23.9M | — | ||
| Q2 24 | $16.6M | — | ||
| Q1 24 | $13.7M | — |
| Q4 25 | $52.2M | — | ||
| Q3 25 | $9.0M | $-84.7M | ||
| Q2 25 | $12.4M | — | ||
| Q1 25 | $12.2M | — | ||
| Q4 24 | $54.9M | — | ||
| Q3 24 | $20.4M | — | ||
| Q2 24 | $14.4M | — | ||
| Q1 24 | $12.2M | — |
| Q4 25 | 73.0% | — | ||
| Q3 25 | 12.8% | -120.1% | ||
| Q2 25 | 17.8% | — | ||
| Q1 25 | 18.0% | — | ||
| Q4 24 | 79.2% | — | ||
| Q3 24 | 29.1% | — | ||
| Q2 24 | 21.6% | — | ||
| Q1 24 | 19.2% | — |
| Q4 25 | 11.0% | — | ||
| Q3 25 | 2.4% | 0.2% | ||
| Q2 25 | 2.3% | — | ||
| Q1 25 | 5.2% | — | ||
| Q4 24 | 16.9% | — | ||
| Q3 24 | 4.9% | — | ||
| Q2 24 | 3.3% | — | ||
| Q1 24 | 2.4% | — |
| Q4 25 | 4.10× | — | ||
| Q3 25 | 0.86× | — | ||
| Q2 25 | 1.01× | — | ||
| Q1 25 | 1.15× | — | ||
| Q4 24 | 4.63× | — | ||
| Q3 24 | 2.80× | — | ||
| Q2 24 | 1.41× | — | ||
| Q1 24 | 1.22× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
